KR-20260067830-A - Composition for preventing, ameliorating or treating olfactory disorder comprising a radiation irradiated chrysin compound as an active ingredient

Abstract

The present invention relates to the use of nicotinamide adenine dinucleotide (NAD) for the prevention or treatment of olfactory disorders. Since the NAD can effectively restore lost olfactory senses by increasing the thickness of olfactory epithelial tissue and promoting the proliferation of olfactory stem cells and differentiation into olfactory neurons, it can be usefully utilized for the prevention, improvement, or treatment of olfactory disorders.

Inventors

• 김지희
• 유신혁

Assignees

• 재단법인 아산사회복지재단
• 울산대학교 산학협력단

Dates

Publication Date

20260513

Application Date

20241106

Claims (9)

1. A pharmaceutical composition for the prevention or treatment of olfactory disorders comprising nicotinamide adenine dinucleotide (NAD).
2. In claim 1, A pharmaceutical composition wherein the above-mentioned olfactory disorder is at least one disease selected from the group consisting of anosmia, hyposmia, hyperosmia, dysosmia, anosmia and phantomosmia.
3. In claim 1, A pharmaceutical composition in which the above-mentioned olfactory disorder is anosmia.
4. In claim 1, The above pharmaceutical composition is a pharmaceutical composition intended for nasal administration.
5. In claim 1, The above pharmaceutical composition is a pharmaceutical composition that increases the thickness of the olfactory epithelial tissue.
6. In claim 1, The above pharmaceutical composition is a pharmaceutical composition that promotes the proliferation of olfactory stem cells.
7. In claim 1, The above pharmaceutical composition is a pharmaceutical composition that increases the differentiation of olfactory stem cells into olfactory neurons.
8. A quasi-drug for the prevention or improvement of olfactory disorders containing nicotinamide adenine dinucleotide (NAD).
9. In claim 8, The above-mentioned quasi-drug is a quasi-drug intended for nasal administration.

Description

Composition for preventing, improving, or treating olfactory disorder comprising a radiation irradiated chrysin compound as an active ingredient The present invention relates to a composition for the prevention, improvement, or treatment of olfactory disorders comprising nicotinamide adenine dinucleotide as an active ingredient. The sense of smell is an important sense that enables us to perceive changes or dangers in the surrounding environment and plays a significant role in the quality of life. Therefore, when an olfactory disorder occurs, not only does it lower an individual's quality of life, such as the loss of the pleasure of eating due to the inability to smell food, but it can also lead to serious problems that threaten life, as the sense of smell acts as a defense mechanism against harmful gases or spoiled food, making it difficult to respond appropriately to the surrounding environment. However, due to the impact of rapid industrialization and modernization, contact with pollutants and chemicals that can act as olfactory toxins in the living environment has increased, leading to a growing prevalence of olfactory disorders. Upper respiratory tract infections, aging, diabetes, and smoking have been reported as causes of olfactory disorders. Various treatments for such olfactory disorders have been proposed to date, including the use of steroids, vitamins, strychnine, zinc, and aminophylline. However, it has been reported that no drug or treatment method, including steroids, has yet shown a high cure rate in patients with olfactory disorders, and most patients are currently being neglected. Against this technical background, the applicant has confirmed that nicotinamide adenine dinucleotide (NAD) can effectively restore lost olfaction by increasing the thickness of olfactory epithelial tissue and differentiating olfactory stem cells into olfactory neurons; thus, the present invention is expected to be usefully utilized for the prevention, improvement, or treatment of olfactory disorders. Figure 1 shows the experimental process of performing behavioral experiments after treating a mouse model of olfactory loss prepared by treating with ZnSO₄ with NAD (nicotinamide adenine dinucleotide) or dexamethasone. Figure 2 shows a schematic diagram of behavioral experiments (buried food test and T-maze test) in which mice are made to find hidden food to test olfactory function in a mouse model of olfactory loss. Figure 3 shows the results of measuring the time it takes for mice to find food by performing behavioral experiments after administering NAD intranasally or intraperitoneally, or dexamethasone intraperitoneally, to a mouse model of olfactory loss. Figure 4a shows H&E stained images of olfactory epithelial tissue collected after administering NAD intranasally or intraperitoneally, or dexamethasone intraperitoneally, to a mouse model of olfactory loss. Figure 4b compares the thickness of olfactory epithelial tissue after administering NAD intranasally or intraperitoneally, or dexamethasone intraperitoneally, to a mouse model of olfactory loss. Figure 5 shows images of olfactory epithelial tissue collected and subjected to immunofluorescence staining after administering NAD intranasally or dexamethasone intraperitoneally to a mouse model of olfactory loss, and the results of measuring the number of cells expressing the olfactory neuron marker OMP (olfactory marker protein) and the neuron marker Tuj1 (beta-III tubulin). Figure 6 shows the results of measuring the expression levels of SOX2 and Nestin, which are proliferation-related markers of olfactory stem cells, and the expression levels of OMP and Tuj1, which are olfactory neuron markers, after treating olfactory stem cells with NAD. The present invention will be described in detail below. 1.Pharmaceutical composition for the prevention or treatment of olfactory disorders One aspect of the present invention provides a pharmaceutical composition for the prevention or treatment of olfactory disorders comprising nicotinamide adenine dinucleotide (NAD). The above NAD is a coenzyme composed of two nucleotides linked by a phosphate group; it plays an essential role in energy production processes such as cellular respiration by transferring electrons in redox reactions during metabolism, and has the structure of Chemical Formula 1 below: [Chemical Formula 1] . The above NAD can effectively restore lost olfaction by increasing the thickness of olfactory epithelial tissue and promoting the proliferation of olfactory stem cells and differentiation into olfactory neurons, and can be usefully utilized for the prevention, improvement, or treatment of olfactory disorders. In the present invention, "prevention" refers to any act of suppressing a specific disease or disorder or delaying its onset by administering a pharmaceutical composition according to the present invention, and "treatment" refers to any act of improving or beneficially altering the symptoms of a spec